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ABSTRACT
Background: Osteosarcoma accounts for roughly 60% of all malignant bone 
tumors in children and young adults. The five-year survival rate for localized tumors 
after surgery and chemotherapy is approximately 70% whilst it drastically reduces 
to 15–30% in metastatic cases. Metabolic modulation is known to increase sensitivity 
of cancers to chemotherapy. A novel treatment strategy in Osteosarcoma is needed 
to battle this devastating malady.
Results: Electroporation-delivered metabolic modulators were more effective in 
halting the cell cycle of Osteosarcoma cells and this negatively affects their ability 
to recover and proliferate, as shown in colony formation assays. Electroporation-
delivered metabolic modulators increase the sensitivity of Osteosarcoma cells to 
chemotherapy and this combination reduces their survivability.
Conclusion: This novel treatment approach highlights the efficacy of 
electroporation in the delivery of metabolic modulators in Osteosarcoma cells, and 
increased sensitivity to chemotherapy allowing for a lower dose to be therapeutic.
Methods: Metabolic modulations of two Osteosarcoma cell lines were performed 
with clinically available modulators delivered using electroporation, and its 
combination with low-dose Cisplatin. The effects of Dicholoroacetic acid, 2-Deoxy-
D-glucose and Metformin on cell cycle and recovery of Osteosarcoma cells were 
assessed. Their sensitivity to chemotherapy was also assessed when treated in 
combination with electroporation-delivered metabolic modulators.
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INTRODUCTION
Osteosarcoma (OS) is of mesenchymal tissue 
origin and is the most common aggressive malignancy 
in children and young adults. It accounts for 2.4% of 
all pediatric malignancies worldwide. The estimated 
average survival rate of patients with OS following 
diagnosis at metastatic stage (15 to 30%) is four to five 
years [1, 2]. This is likely due to the high propensity of 
OS to haematologically metastasize early and progress 
rapidly given its primary sites with rich blood supply e.g. 
metaphysis of distal femur, proximal tibia and humerus. 
Current gold standard treatment involves use of high-
dose neoadjuvant chemotherapies followed by en bloc 
resection of the cancer, which may include amputation in 
some cases. The overall survival rates in OS patients have 
not improved despite recent developments and advances in 
treatment strategies, prompting rigorous study of possible 
means of treating OS. Treatments for OS now include 
gene, targeted, and immunotherapy with progress in 
molecular biology [3–5].
The physiological states in cancer have resulted in 
complex regulatory mechanisms of cellular metabolism 
[6]. Cancer cells co-opt this normal regulation to fuel 
           Research Paper
Oncotarget31474www.oncotarget.com
inappropriate cell proliferation and support survival in 
abnormal tissue contexts, leading to differed metabolism 
of tumor tissues from that of normal tissues from which 
cancer arises [7–9]. Cancer cells depend mainly on 
glucose metabolism for their energy production and 
macromolecular synthesis. The shift to aerobic glycolysis 
from mitochondrial respiration in rapidly proliferating 
tumor cells is a characteristic hallmark - a phenomenon 
known as the Warburg effect [10]. The high biomass 
requirements of rapid proliferating cancer cells are fulfilled 
by aerobic glycolysis, although it is inefficient from an 
energetic aspect [11]. The distinct metabolism of tumor 
cells makes targeting of metabolic pathways a promising 
approach for therapeutic interventions. Several metabolic 
modulators that alter essential malignant cell survival 
pathways have been developed with some success in recent 
years [12]. However, the success of metabolic modulating 
agents in cancer depends on a better understanding of their 
mechanism and identification of the ideal tumor type to 
target. It is also important to study these modulators as 
both single agents and in combination with other agents. 
The adequacy of treatment demographics i.e. dosing and 
schedule, tumor type and treatment response evaluation 
remain uncertain although these drugs have been tested in 
clinics. Glucose analogue 2-deoxy-D-glucose (2DG) used 
in renal cell carcinomas resulted in dose-limiting toxicities 
such as fatigue, sweating, and prolonged corrected QT 
(QTc) interval in electrocardiography (EKG) [13–15].
To a large extent, neo-adjuvant chemotherapy 
in OS has resulted in limb-salvage surgery replacing 
conventional amputation. Having said that, there is 
no consensus on whether neo-adjuvant chemotherapy 
improves the long-term prognosis of patients. Only 60% 
of OS patients respond to chemotherapy. The efficacy 
of these routinely used single chemotherapeutic agents 
in the treatment of OS (based on histological type) had 
plateaued. Resistance to chemotherapy could also be due 
to intrinsic chemotherapeutic resistance developing prior to 
chemotherapy as well as acquired resistance occurring after 
several cycles of treatment, which led to the introduction 
of double chemotherapy agents in the treatment of OS. 
The current treatment protocol in OS includes a cocktail 
of chemotherapeutic agents e.g. Cisplatin, Doxorubicin, 
Ifosfomide and an addition of high-dose Methotrexate. 
This first-line therapy is indicated in primary or metastatic 
disease states, and also as neoadjuvant or adjuvant 
therapies. Neoadjuvantly, the regular dose for Cisplatin 
given continuously as an infusion via intravenous route 
for 24 hours is 100 mg/m2, in addition to boluses of 
Doxorubicin for three days [16]. An essential aspect of 
OS management includes considering the toxicities from 
these chemotherapy agents and their side effects such as 
ototoxicity and/or hearing loss, myelosupression and risk of 
neutropenic sepsis or hemorrhage, ammenorhea, infertility, 
nephro- and cardiotoxicity, peripheral neuropathy and 
second malignant neoplasms (carcinogenesis). Reducing 
the chemotherapy dose concentrations and their 
complications in OS treatment is an important goal that 
will require the development of other treatment options and 
improved antidotes for the active anti-OS drugs. A novel 
strategy that efficiently inhibits growth and metastasis of 
OS is highly warranted.
Electroporation (EP) is a physical method of 
electrical application that allows permeabilization of cell 
membranes. This allows and facilitates the uptake of ions 
and compounds into cells across the cell membranes. A 
benefit to this approach is that a lower concentration of 
compounds can be used to achieve a similar if not better 
effect on cells or tumor. Clinically available metabolic 
modulators such as Dichloroacetic acid (DCA) are 
negatively charged molecules, whilst Metformin and 
2DG are neutral. Irreversible electroporation (IRE) has 
been shown to be an effective technique for ablating 
human metastatic OS [17, 18]. There is no data to show 
the delivery of metabolic modulators using reversible EP 
in the treatment of cancers, particularly OS.
The combined treatment comprising of metabolic 
modulators and chemotherapy could be an intriguing 
approach for the treatment of patients with OS. 
Understanding the potential benefits of combining these 
two treatment modalities could be important in developing 
optimal treatment strategies for patients with advanced 
OS. Currently, no prospective data on this combination 
treatment is available. In this study, we examined the 
morphologies, cell cycles and effects on recovery and 
proliferation, and survival of OS cells treated with 
different metabolic modulators (delivered using reversible 
EP) in combination with low-dose Cisplatin. 
RESULTS
Morphology of osteosarcoma cells post EP 
optimization
The murine K7M2 cell line and the human Saos2 
cell line were maintained at their active growth phase and 
their morphological changes evaluated post EP at different 
field intensities. Voltage ranges used were 0 to 1.25 kV/cm 
for both cell lines, with an increment of 0.25 kV/cm 
between groups. After EP, cells were cytospun and stained 
to study its cellular morphology at 24 hours.
Figure 1 presents the ultrastructural morphological 
changes of K7M2 (Figure 1A) and Saos2 (Figure 1B) 
OS cell lines at 24 hours post EP, at different field 
intensities (represented by voltage) (range of 0 to 
1.25 kV/cm). No significant morphological changes 
were observed in the untreated groups in both cell lines. 
Both untreated groups showed well-rounded, smooth and 
regular-surfaced cells. As higher voltages were applied, 
more intracytoplasmic vacuoles (arrow) were observed 
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alongside increase in size of the swollen cells. Blebbing 
of cellular membranes (right-angle arrow) of cells in 
both groups also were observed at higher voltages. 
Voltages of above 1.0 kV/cm for K7M2 and 0.75 kV/cm 
for Saos2 showed leakage of cytoplasmic material (red 
triangle) as a result of irreversible EP causing rupture 
of cellular membranes. There were more ‘ghost-like’ 
(black triangle) appearances of dead cells seen in 
field intensities higher than 0.75 kV/cm for K7M2 and 
0.5 kV/cm for Saos2. Red boxes indicate the optimal 
voltages of reversible EP for each cell line. These voltages 
were derived from the combination of morphological 
changes, viability and PI uptake of cells post EP.
Propidium iodide uptake and viability post EP
EP at different voltages (0 to 1.25 kV/cm) were 
applied to both K7M2 and Saos2 cells in the presence of a 
non-permeant dye, propidium iodide (PI). The efficiency 
of EP was evaluated by the penetration of PI, and uptake 
across the cell membrane using flow cytometry. Figure 1C 
and 1D present flow cytometry dot plots of K7M2 & Saos2 
cells respectively that were electroporated in the presence 
of PI at ascending voltages. The red populations (dots) 
represent non-viable cells, whilst the black populations 
(dots) are viable (Figure 1C, 1D). It is evident that both OS 
cell lines take up more PI at higher EP voltages. However, 
there was a slight decrease in PI uptake of viable K7M2 
cells at 1.25 kV/cm compared to 1 kV/cm, but a higher 
count of non-viable cells at this voltage. Both cell lines 
showed a direct proportional increment of PI uptake with 
increased EP voltages, with the highest uptake at 1 kV/cm 
for K7M2 and 1.25 kV/cm for Saos2 cells (Figure 1E). 
There were a higher number of dead cells observed 
at 1 kV/cm based on morphology of K7M2 cells (black 
triangle, Figure 1A), and decreased viability over 96 hours 
(Figure 1F). Increased cell death at this voltage was due to 
IRE caused by high voltages from EP. Morphologically, 
there were fewer dead K7M2 cells at 0.75 kV/cm compared 
to 1.25 kV/cm (Figure 1A). Viability of K7M2 cells at 
0.75 kV/cm was over 90% at 48 hours (Figure 1F). 
Therefore, we concluded the optimum voltage/field 
intensity was 0.75 kV/cm for K7M2 (red box Figure 1F) 
based on a combination of morphological changes, viability 
of cells and PI uptake. 0.75 kV/cm was the voltage used for 
all subsequent experiments involving K7M2 cells. 
Saos2 cells also showed a direct proportional 
increment of PI uptake as higher EP voltage were applied, 
with the highest uptake at 1.25 kV/cm (Figure 1E). 
However, there were fewer viable Saos2 cells observed 
morphologically above 0.5 kV/cm (Figure 1B), therefore 
making it the optimum voltage (red box Figure 1G) 
for reversible EP, allowing PI to enter the cells and 
yet maintaining their viability at 90% over 96 hours 
(Figure 1G). 0.5 kV/cm was the voltage used for all 
subsequent experiments involving Saos2 cells. 
Effects of metabolic modulators delivered using 
EP relative to modulators alone
The optimum concentrations of the candidate 
metabolic modulators were obtained by a series of dose 
responses on OS cells, treated actively (with EP) and 
passively (without EP). There were notably higher 
numbers of dead K7M2 (Figure 2A) and Saos2 (Figure 2B) 
cells seen morphologically in groups treated with actively 
delivered metabolic modulators for 24 hours (optimized 
concentration). Dead cells were defined morphologically 
as cells that had lost their plasma membrane integrity 
leading to the loss of cell’s identity, cell fragmentation, or 
engulfment by adjacent cells [19]. In these two figures, 
the black arrows show intracytoplasmic vacuoles as a 
result of EP, and black triangles show dead cells. In the 
EP-delivered treatment groups for both cell lines, there 
was a slight increase of total dead cells. The ability of 
K7M2 and Saos2 cells to recover and proliferate after a 
24-hour treatment with metabolic modulators delivered 
actively was significantly reduced compared to the groups 
treated with modulators alone (Figure 2C, 2D), assessed 
by colony formation assay. Active delivery of DCA was 
most effective in inhibiting the recovery in both cell lines. 
Data was statistically significant with values of p < 0.05 
throughout all treatment groups. These findings suggest an 
increased uptake of metabolic modulators when delivered 
actively by EP, allowing them to exert their potency on 
OS cells more effectively i.e. halting their cell cycle 
allowing for reduced rate of proliferation. We conclude 
that delivering metabolic modulators using EP negatively 
affects the ability of OS cells to recover and proliferate 
over a period of time.
Effects on cell cycle by metabolic modulators in 
combination with EP
In order to assess the effects of these clinically 
available metabolic modulators in combination with EP, 
we looked at their cell cycle effects on both K7M2 and 
Saos2 cells. Both cell lines were treated passively and 
actively for 8 and 24 hours at the following concentrations 
- DCA at 10 mM, 20 mM and 30 mM for K7M2 and 1 mM, 
5 mM and 10 mM for Saos2 cells, 2DG and Metformin at 
1 mM, 5 mM and 10 mM for both cell lines. Paclitaxel 
5 uM was used as a positive control in this experiment. 
Figure 3C presents representative histograms of K7M2 
and Saos2 cells treated with metabolic modulators at the 
optimized concentrations, passively (grey tinted) and 
actively (blue line) for 24 hours (right side of broken red 
line). Control groups (untreated baseline control, EP only, 
and Paclitaxel 5 uM) are shown on the left of the broken 
red line (Figure 3C). 
Cell cycle analysis was performed at 8 and 24-
hour time points. 8-hour treatment with metabolic 
modulators showed little inhibition [Figure 3A(i) and 
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Figure 1: Morphology, PI uptake and viability of K7M2 and Saos2 cell lines post EP optimization. Both cell lines were 
electroporated with eight 99 us pulses with a voltage-to-distance ratio ranging from 0.25 to 1.25 kV/cm. Cells were rested for thirty minutes 
prior to seeding in 6-well plates, harvested at 24 hours then cytospun and stained for morphological evaluation of (A) K7M2 and (B) Saos2 
cells. Black arrows indicate intracytoplasmic vacuoles, black triangles show dead cells, right-angled arrows show blebbing of cellular 
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3B(i)]. However, at 24 hours EP-delivered DCA showed 
a pronounced inhibition of K7M2 cells at G0/G1 phase 
and increased G2/M phase compared to the groups that 
were passively treated [Figure 3A(ii)]. There was also an 
increment in the S phase of K7M2 cells in the EP DCA 
group [Figure 3A(ii)], suggesting failure of progression 
of these cells from the S to G2/M phases in their cell 
cycle. EP delivered DCA also showed reduction in G0/
G1 and G2/M of Saos2 cell cycle phases. The G2/M 
phase of this cell line were halted at higher concentrations 
of DCA [Figure 3B(ii)]. K7M2 cells treated with 2DG 
using EP also showed stalling of their cell cycle at the 
G0/G1 phase at higher doses, causing a lesser degree 
of replication of these fast-growing cells due failure of 
progression to G2/M phase. In the Saos2 group, it was 
observed that EP delivered 2DG had reduced in the 
G2/M phase compared to those treated passively [Figure 
3B(ii) and 3c]. EP delivered Metformin in the K7M2 
cells showed little reduction in the G2/M phase but an 
increase in G0/G1 phase compared to the passively treated 
group, implying that these groups of cells had also failed 
to progress in their cell cycle. Further, a decrease in the 
G0/G1 and G2/M phases of Saos2 cells treated actively 
with Metformin was seen [Figure 3B(ii)]. On the whole, 
a greater effect of these metabolic modulators delivered 
using EP was seen in the K7M2 compared to Saos2 cells. 
This was likely due to the nature of K7M2 cells having a 
higher proliferation rate.
The optimum concentration of metabolic modulators 
delivered using EP were decided based on their effects on 
the OS cell cycles analyzed using flow cytometry and 
cellular morphological changes from dose responses (data 
not shown). We conclude that OS cells treated actively 
with metabolic modulators have a higher effect on halting 
OS cells at different phases of their cell cycle compared to 
passive treatment.
Viability and morphological changes post 
combined treatment
Depletion of intracellular ATP levels in cancer cells 
increases their sensitivity towards chemotherapy [20]. A 
dose response to Cisplatin was performed on both cell 
lines to reach an optimum low-dose concentration. We 
assessed the viability and morphological changes in OS 
cells post combined treatment over a specific period of 
time (Figure 4A–4F). A reduced total number of K7M2 
and Saos2 cells were seen in the combined treatment 
groups over 48 hours (Figure 4A, 4C). Also, there were 
more dead cells in these groups (black triangle). Viability 
of OS cells decreased over 48 and 96 hours (Figure 4E, 4F) 
when treated with the combined approach – delivery of 
metabolic modulators using EP and low-dose Cisplatin. 
This was more pronounced in the Saos2 cells (Figure 4F). 
K7M2 cells treated with EP-delivered 2DG combined 
with Cisplatin showed highest viability amongst the 
combined-treatment groups over a 96-hour period, 
possibly suggesting a prosurvival pathway of 2DG treated 
cells [21].
Recovery and sensitivity of osteosarcoma cells 
post treatment with combination approach
Reversible EP has the potential to increase the 
uptake and potency of metabolic modulators in OS cells 
thus reducing their cell cycle and depleting intracellular 
ATP levels. Reduced ATP levels potentiate sensitivity 
of cancer cells to, and enhance the effects of low-dose 
chemotherapeutics [20, 22]. We assessed this theory in OS 
cells by looking at their recovery and colony formation 
post combined treatment. It is evident that OS cells treated 
with the combination approach negatively affects the 
ability of these cells to recover and proliferate, compared 
to the other treatment groups (Figure 4G, 4H). The 
optimum combination treatment was EP-delivered DCA 
combined with Cisplatin for both cell lines (dashed red 
box in Figure 4G, 4H). This was statistically significant 
(p < 0.05) across all combined treatment groups compared 
to others. The sensitivity assay was set up to determine 
the efficacy of low-dose Cisplatin in OS cells that were 
initially treated actively with metabolic modulators. The 
ability of OS cells to form colonies in Cisplatin-treated 
media over a period of time reduced in the combination 
treatment groups in both cell lines (Supplementary 
Figure 1A, 1B). 
DISCUSSION
In the present study, we used Osteosarcoma cells to 
evaluate the combination effect of metabolic modulators 
delivered using reversible EP, followed by the addition of 
low-dose chemotherapy 24 hours later. To our knowledge 
we are the first to report the delivery of metabolic 
modulators using reversible EP. The optimum EP 
membrane, and red triangles show cytoplasmic material leakage. Morphology images are representative of at least three independent 
experiments. Data also presented as bar graphs of percentage of dead cells post treatments. *statistically significant difference in the 
percentage of dead cells treated with metabolic modulators for 24 hours, with and without using EP (p < 0.05), **p < 0.01. EP efficiency was 
represented by population shift of viable cells (represented by black dots on dot plot) in (C) K7M2 and (D) Saos2, along Y-axis on flow 
cytometry dot plots, also plotted as bar graph in (E) for both cell lines. *statistically significant difference in the percentage of PI uptake of 
viable cells electroporated at different voltages (p < 0.05), ***p < 0.001. Viability of (F) K7M2 and (G) Saos2 cells were measured by flow 
cytometry at 48 and 96 hours post EP at different voltages. *statistically significant difference in the percentage of viable cells post EP at 
different voltages (p < 0.05), ns = no significance, *p < 0.05, **p < 0.005. Untreated = untreated baseline control cells. Red dashed boxes 
indicates the optimal voltage for each cell line.
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delivery parameters for these cell lines were determined. 
Morphologically, there were fewer cells when treated 
with metabolic modulators actively compared to the 
passive groups. This was consistent with their decreased 
recovery and survival (colony formation) over a period 
of time for both cell lines. In our data, we have shown 
that when combined with reversible EP, DCA, 2DG and 
Metformin, were able to significantly halt murine and 
human OS cell cycles at different phases of cell cycle. 
There was also a decrease in viability when EP-delivered 
metabolic modulators were combined with low-dose 
Cisplatin, consistent morphologically with the increased 
number of dead cells in the combined treatment groups. 
We also observed fewer cells in the combined treatment 
groups suggesting an increase in sensitivity of OS cells to 
low-dose chemotherapy, indicating an increase in synergy 
between these two drug classes. Finally, the OS cells’ 
ability to recover and proliferate was significantly reduced 
when treated using the combined method thus reducing 
their survival.
As mentioned previously, the gold-standard therapy 
for OS consists of multi-agent neoadjuvant chemotherapy 
followed by radical surgery and adjuvant chemotherapy. 
Survival outcomes of patients with OS have not improved 
Figure 2: Morphology and recovery of K7M2 and Saos2 cell lines treated with metabolic modulators delivered using 
EP relative to modulators alone. Morphologies of (A) K7M2 and (B) Saos2 cell lines at 24 hours post EP in the presence or absence 
of different metabolic modulators at their optimized concentration. Data also presented as bar graphs of percentage of dead cells post 
treatments [(A) and (B)]. *statistically significant difference in the percentage of dead cells treated with metabolic modulators for 24, with 
and without using EP (p < 0.05), **p < 0.05. The effects of metabolic modulators delivered with and without using EP on recovery of (C) 
K7M2 and (D) Saos2 cell lines were quantified by fluorescent intensities of colony formation over a period of time. Each well shown is a 
representative image of at least nine similar wells (three independent experiments). Data also presented in bar graphs as mean integrated 
intensity ± SEM of three independent experiments. *statistically significant difference in the number of colonies formed when cells were 
allowed to recover post metabolic modulator treatments delivered with and without using EP (p < 0.05), *p < 0.05 **p < 0.005 and *** p < 
0.001. Unt = untreated baseline control. 
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despite attempts to refine therapy efficacy e.g. via 
combinations of chemotherapy and radiotherapy especially 
in inoperable cases, and chemotherapy dose escalations 
[23–31]. Cell cycle alterations are excessively implicated in 
tumorigenesis, genomic instability and drug resistance [32–
34]. Recent efforts to expand opportunities for treatment 
of OS through rigorous preclinical drug development, 
comprehensive genomic analyses, and the implementation 
of a histology-exclusive clinical trial model for the 
investigation of new agents are now beginning to generate 
a number of therapeutic strategies to be implemented in 
upcoming studies. This combination therapy of metabolic 
modulators and low-dose chemotherapy is not only 
effective in battling the survival of OS, but also less 
invasive as the metabolic modulators can be delivered 
using reversible EP intra-tumorally and followed by 
systemic administration of low-dose chemotherapy. We 
are optimistic that this new preclinical investigation on 
combination therapy in OS will identify a niche that can be 
moved forward to new trials in treatment regimes, with the 
goal of improving long-stagnant survival outcomes.
EP facilitates the intracellular uptake of substances 
that are otherwise difficult to enter cells, making it a 
popular technique for cell loading. This results in a higher 
intracellular concentration of compounds. In the treatment 
of cancer, EP technology has advanced tremendously 
leading to development of electrochemotherapy (ECT) 
and its increased anti-tumor effects [35]. Today, EP is 
used in many clinical and biotechnological applications. A 
clinical trial on soft tissue tumor is ongoing at the Sarcoma 
and Melanoma Unit of Padova. This trial extends ECT 
indications to patients with advanced and deep-seated 
cancers, where longer electrodes and bespoke insertions 
are used in this trial to generate an electric field tailored to 
the tumor mass and its margins. This is aimed at obtaining 
a higher local response and tumor control even on a large 
or deep tumor with a single treatment. Drug delivery using 
EP is found to be less painful [36] and may represent a 
favorable minimally invasive alternative to wide surgical 
resection, at least in a subgroup of sarcoma patients. On 
the basis of high efficacy of ECT [37–42], clinicians and 
researches are developing strategies to extend the use of 
Figure 3: Effects of metabolic modulators on cell cycle of both OS cell lines. Cell cycle phases at 8 hours K7M2 [A(i)] and 
Saos2 [B(i)], and 24 hours K7M2 [A(ii)] and Saos2 [B(ii)] were analyzed and quantified after fixing and staining both cell lines with PI. 
The DNA content were analyzed using flow cytometry. Bars with red borders in (A) and (B) represent actively (using EP) treated groups. In 
(C), the control group histograms (left of broken red line) are as follows: grey tint – untreated baseline control, red line – positive control, 
blue line – EP only group. Cell cycle effects post treatment with metabolic modulators at the optimized concentrations delivered actively 
or passively were analyzed and their representative histograms are shown in (C) for K7M2 and Saos2 cell lines. Histograms on the right of 
the broken red line: grey tint – passive treatment, blue line – active treatment. 
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EP-delivered therapy to deep seated and visceral tumors. 
The development of EndoVe System led to the clinical trial 
of endoscopic treatment of inoperable colorectal cancer 
in Ireland. Results from the ESOPE trial demonstrated 
an 85% objective response rate in solid cutaneous and 
subcutaneous tumor of varying histologies [43]. EP 
combined with Methotrexate has been employed with 
success in tumor-bearing mice with implanted OS cells 
[44]. The NanoKnife, an IRE device, was used to treat 
metastatic OS lung lesions [17]. IRE was also shown to 
be more effective in ablating the tumor than conventional 
treatment in OS-bearing mice [18]. To date, there is no 
published data on the usage of reversible EP drug delivery 
in OS.
One common feature of cancer cells is their ability 
to use glycolysis instead of oxidative phosphorylation 
to produce energy, despite its disease heterogeneity with 
diverse alterations [45, 46]. At first, a ‘faulty’ respiratory 
chain was thought to be the cause of these differences 
leading to the increase in glycolysis by tumor cells as a 
compensatory mechanism to this defect. But, if cancer cells 
(relative to normal cells) increase glucose metabolism – to 
form pyruvate and NADPH as a compensatory mechanism 
in response to Reactive Oxygen Species (ROS) formed 
as byproducts of oxidative energy metabolism – then 
inhibition of glucose metabolism would be expected to 
sensitize cancer cells to agents that increase the levels of 
hydroperoxidases (i.e., chemotherapy agents such platinum-
Figure 4: Morphology, viability and the recovery of K7M2 and Saos2 cell lines post combination treatment. Morphologies 
of (A) K7M2 and (C) Saos2 cell lines at 24 and 48 hours post EP in the presence or absence of metabolic modulators, with and without 
the combination of low-dose Cisplatin. Cells were harvested at specific time points and cytospun and stained for morphological evaluation 
under light microscopy. Data also presented as bar graphs of percentage of dead cells post treatments [(B) and (D)]. *statistically significant 
difference in the percentage of dead cells treated with combination treatment for 24 and 48 hours, with and without using EP (p < 0.05), 
*p < 0.05, **p < 0.005 and *** p < 0.001. In (A) and (C) black arrows represent intracytoplasmic vacuoles and black triangles show dead 
cells. Viability of (E) K7M2 and (F) Saos2 was assessed 48 and 96 hours later by PI uptake using flow cytometry. *statistically significant 
difference in the percentage of viable cells treated with combination treatment for 48 and 96 hours, with and without using EP (p < 0.05), 
*p < 0.005, **p < 0.05. The recovery of (G) K7M2 and (H) Saos2 cell lines post combination treatment was quantified by fluorescent 
intensities of colonies formed. Each well shown is a representative image of at least nine similar wells (three independent experiments). 
Data also presented in bar graphs as mean Integrated Intensity ± SEM of three independent experiments. *statistically significant difference 
in the number of colonies formed when cells were allowed to recover post metabolic modulator treatments delivered with and without using 
EP combined with low-dose Cisplatin (p < 0.05), *p < 0.05, **p < 0.01 and ***p < 0.001. 
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based therapeutics e.g. Cisplatin and quinones, known to 
redox cycle and produce ROS [47]. The increase in synergy 
between metabolic modulation and chemotherapy has been 
validated in colon carcinoma and lymphoma in in vivo 
studies [48]. Resistance to chemotherapeutics is promoted 
by an increase in tumor cells’ glycolytic rate. Accumulating 
data also indicate that intracellular ATP is a critical 
determinant of chemoresistance [49]. We demonstrated this 
finding in our study. OS cells showed enhanced sensitivity 
and synergy to induce cell death, and reduced recovery 
and proliferation when combined with low-dose Cisplatin, 
suggesting the enhanced therapeutic benefit of combined 
therapy of metabolic modulators delivered using reversible 
EP with chemotherapy in vitro.
Hair and hearing loss, gonadal and cardiac 
dysfunction, and infections associated with myositis, 
myelosuppression and impaired renal function are the most 
frequent complications associated with chemotherapy. 
As a result, long-term follow-up is required not only to 
monitor the remission status but also in order to screen for 
and manage late effects occurring following completion 
of the chemotherapy regime [50]. These adverse effects 
of chemotherapy can be minimized with the use of 
lower dose chemotherapies, given the increased synergy 
when combined with metabolic modulators delivered 
using reversible EP, as shown in our data. We propose 
this combination therapy as a novel addition to the 
armamentarium of treatments in OS.
MATERIALS AND METHODS
Cell culturing
Two cell lines were used in the experiments, the 
established human OS cell line Saos2 [51] and the murine 
OS cell line K7M2 [52]. Both cell lines were obtained 
from American Type Culture Collection (ATCC), 
Massachusetts. Saos2 cells were maintained in McCoy 
5A media (ATCC) supplemented with 20% (v/v) fetal calf 
serum (Sigma, F7524). K7M2 cells were maintained in 
Dulbeccos Modified Media (DMEM) (Sigma, D6429) 
with 10% (v/v) fetal calf serum. Both cell lines were 
supplemented with 1% penicillin/streptomycin, and were 
cultured at 37° C, 5% CO2.
Metabolic modulators
The concentration ranges for 2DG and Metformin 
used in both cell lines were 1, 5 and 10 mM. DCA 
concentration range for K7M2 cells was 10, 20, and 
30 mM whilst for Saos2 cells were 1, 5, and 10 mM.
Electroporation protocol
Following harvesting, 1 × 106 K7M2 and 5 × 105 
Saos2 cells were resuspended in 800 ul serum-free DMEM 
and serum-free McCoy 5A respectively, and electroporated 
in 4 mm cuvettes (VWR) in the presence of DCA (K7M2: 
10, 20, 30 mM; Saos2: 1, 5, 10 mM), 2DG (1, 5, 10 mM) 
and Metformin (1, 5, 10 mM). The EP parameters used 
were as follows: 8 pulses of 99 us at a frequency of 1Hz at 
various voltages – 0 to 1.25 kV/cm for both cell lines using 
a BTX electroporator (Harvard apparatus, Model ECM 
2001). After the application of electric pulses, cells in 
cuvettes were left to rest in the incubator for thirty minutes 
prior to seeding in 6-well plates for individual experiments. 
Parameters for each cell line were optimized for high 
permeabilization and low cell death from EP alone.
Evaluation of morphology
Morphological features of cells treated with DCA 
(Sigma, D54702), 2DG (Sigma, D6134), Metformin 
(Abcam, ab146725), and Cisplatin (Teva Pharma. BV) 
were examined by light microscopy. Drug-treated cells 
(active and passive treatment) were cytospun onto glass 
slides and stained using Pro-Diff (Braidwood Laboratories 
BAPROD1-fixed and stained with buffered eosin followed 
by methyl thionins). Cytospin images are representative 
of at least three independent experiments. Dead cells were 
defined morphologically as cells that had lost their plasma 
membrane integrity leading to the loss of cell’s identity, 
cell fragmentation, or engulfment by adjacent cells [19].
Propidium iodide uptake
K7M2 & Saos2 cells were applied with electrical 
pulses (EP) at different voltages using the above-
mentioned parameters for each cell line, in the presence of 
PI (5 ug/100 ul). Samples were analyzed on the BD LSR 
II instrument for PI uptake measurement.
Propidium iodide viability assay
PI is a small fluorescent molecule that binds to 
DNA but cannot passively traverse into cells that possess 
an intact plasma membrane. PI uptake versus exclusion 
can thus be used to discriminate dead cells, in which 
plasma membranes become permeable regardless of 
the mechanism of cell death, from live cells with intact 
membranes. Cells were seeded at 2.5 × 104 cells/ml and 
1.25 × 104 cells/ml (K7M2) and 4 × 104 cells/ml and 
1.85 × 104 cells/ml (Saos2), for 48 or 96-hour treatments 
respectively with DCA, 2DG, or Metformin, in 2 ml/well 
total volume. After the given time, cells were typsinized, 
washed in PBS and then PI (5 ug/100 ul) was added and 
viability was measured using the BD LSR II instrument.
Colony formation assay
We assessed the ability of cells to recover from 
treatments and form colonies on a monlayer surface. 
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Following treatments, all adherent cells were trypsinized, 
counted and viability determined. Of those viable cells, 
4 × 102 cells/ml (K7M2) and 5 × 102 cells/ml (Saos2) were 
seeded into a 3 ml/well of a six-well plate (in triplicate). 
Cells were allowed to adhere and grow between 10 to 14 
days. To visualize colonies, media was removed, washed 
with Phosphate Buffer Saline (PBS), and cells were fixed 
with 96% ethanol for five minutes and stained with Prodiff 
solution C (Braidwood Laboratories BAPROD1). Plates 
were scanned using the Odyssey IR imaging system 
(Li-Cor, Cambridge, United Kingdom) and colonies 
quantified. Results are presented as integrated intensity ± 
SEM from at least three independent experiments. 
Cell cycle analysis
K7M2 and Saos2 cells were treated with DCA 
(K7M2: 10, 20, 30 mM; Saos2: 1, 5, 10 mM), 2DG (1, 5, 
10 mM) and Metformin (1, 5, 10 mM) for 8 and 24 hours, 
with and without EP delivery. Paclitaxel 5 uM was used as 
a positive control. At these specific time points, cells were 
harvested and fixed in 70% ethanol overnight at −20° C. On 
the following day, these cells were resuspended in 0.5 ml 
PBS containing 20 ug/ml PI and 100 mg/ml DNase free 
RNase A (Qiagen, 19101), and incubated in the dark for 
one hour at room temperature. Samples were then run on 
the BD LSR II instrument for cell cycle analysis.
Combination assay
Following harvesting, both K7M2 and Saos2 cells 
were treated with DCA 30 mM (K7M2) and 10 mM (Saos2), 
2DG 5 mM, and Metformin 10 mM for 30 minutes. These 
metabolic modulator concentrations were optimized prior to the 
combination assay. The actively treated group samples (using 
EP) were given electrical pulses (K7M2: 0.75 kV/cm; Saos2: 
0.5 kV/cm) in 4 mm cuvettes (VWR) - 8 pulses of 99 us at a 
frequency of 1 Hz, and rested at 37° C, 5% CO2 for a further 
30 minutes. All samples were then resuspended in respective 
media and seeded at 4 × 102 cells/ml (K7M2) and 5 × 102 
cells/ml (Saos2) into a 3 ml/well of a six-well plate (repeated 
in triplicate). Cells were washed with PBS on the following 
day, and replaced with Cisplatin-treated media for reciprocating 
combined treated groups: 800 nM (K7M2) and 700 nM 
(Saos2). Cells were allowed to adhere and grow between 10 to 
14 days and analyzed as per colony formation assay.
Sensitivity assay
Sensitivity of both K7M2 and Saos2 cell lines treated 
with metabolic modulators actively or passively, combined 
with low-dose Cisplatin was evaluated by stained colonies 
formed in Cisplatin-treated media. 7 × 102 cells/ml and 
1 × 103 cells/ml for K7M2 and Saos2 cells respectively were 
seeded into a 3 ml/well of a six-well plate (in triplicate). 
Cells were allowed to adhere and grow between seven 
to nine days. To visualize colonies, media was removed, 
washed with Phosphate Buffer Saline (PBS), and cells were 
fixed with 96% ethanol for five minutes and stained with 
Prodiff solution C (Braidwood Laboratories BAPROD1). 
Picture of each well shown is a representative image of at 
least nine similar wells (three independent experiments).
Statistical analysis
Values are presented as the mean ± standard error of 
the mean (SEM) for three independent experiments. We 
performed paired t-test (two-tailed) statistical analysis, 
p < 0.05 was significant. Asterisks indicate the level of 
significance.
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